Special populations
Description:
This web page provides brief recommendations for monitoring patients undergoing buprenorphine treatment using liver function tests, and the proper actions to take if a patient develops hepatitis.
Source:
PCSS Guidance
Tags:
Description:
This consent form -- reproduced with permission from the Boston Medical Center -- can be used with your pregnant patients who want to continue taking buprenorphine during pregnancy.
Source:
Boston Medical Center (1 vote)
Tags:
Description:
Presently, methadone is the recommended treatment for opioid-dependent pregnant women, but is associated with neonatal abstinence syndrome (NAS). NAS is characterized by opioid withdrawal symptoms in the newborn, which often requires longer hospitalization and treatment. Buprenorphine, FDA-approved in 2002 for the treatment of opioid dependence in non-pregnant individuals, hasn't been extensively studied during pregnancy. Yet, a new study in the New England Journal of Medicine (NEJM) found that buprenorphine offers an alternative to methadone in the treatment of opioid-dependent pregnant women. The study compared buprenorphine to methadone in 131 mothers and their newborns at eight international sites.
Source:
New England Journal of Medicine
Tags:
Description:
This document discusses the evidence for buprenorphine treatment of opioid dependent adolescents and young adults. It provides treatment recommendations, and highlights special issues that should be considered when treating this special population.
Source:
Physician Clinical Support System (PCSS)
Tags:
- General information - buprenorphine
- Induction and dosing
- Stabilization and maintenance
- Special populations
- Addiction
- Adolescents
- Comorbidities
- Dependence
- Detoxification
- Diagnosis
- Dosing
- Hepatitis
- Heroin
- HIV/AIDS
- Induction
- Maintenance
- Overdose
- Precautions
- Psychosocial
- Relapse
- Side effects
- Special populations
- Suboxone
- Withdrawal
- Treatment Algorithm
- Experienced prescriber
- Just became waivered
Description:
Developed by a consensus panel, these guidelines provide treatment recommendations for patients with dual disorders.
Source:
U.S. Department of Health and Human Services, SAMHSA
Tags:
- Screening and diagnosis
- Special populations
- Managing challenging patients
- Addiction
- Assessment
- Behavioral therapy
- Comorbidities
- Complicated patients
- Dependence
- Drug interactions
- Expert panel
- Pharmacology
- Pharmacotherapy
- Pharmacy
- Polysubstance use
- Psychiatric
- Psychosocial
- Referral
- Relapse
- Risk factors
- Screening
- Side effects
- Special populations
- Symptoms
- Tolerance
- Withdrawal
- Treatment Algorithm
- Experienced prescriber
- Just became waivered
- Need to refer
Description:
This article provides guidance on the management and treatment of acute pain in patients receiving buprenorphine/naloxone.
Source:
Physician Clinical Support System (PCSS)
Tags:
- General information - buprenorphine
- Induction and dosing
- Stabilization and maintenance
- Special populations
- Logistics of buprenorphine treatment
- Addiction
- Dependence
- Discontinuation
- Dosing
- Induction
- Maintenance
- Methadone
- Pain
- Pharmacology
- Relapse
- Special populations
- Suboxone
- Withdrawal
- Treatment Algorithm
- Experienced prescriber
- Just became waivered
Description:
This information brief discusses the abuse of prescription drugs by young people, commonly abused prescription drugs, and diversion of said drugs.
Source:
National Drug Intelligence Center
Tags:
Description:
This study largely focused on children of parents who abuse alcohol but also contains some information on children of drug users.
Source:
Johnson JL, Leff M.Children of substance abusers: overview of research findings. Pediatrics. 1999;103(suppl 5, pt 2):1085-1099.
Description:
This one-page guide provides basic information for adults on how to help children of addiction (COAs). It also provides additional resources and organizations that can provide further information.
Source:
Center for Substance Abuse Treatment (CSAT)
Tags:
Description:
This journal article compares the effectiveness of detoxification vs. continuing buprenorphine-naloxone therapy for treating opioid-addicted adolescents. The study followed 152 patients between the ages of 15 and 21 who were randomly selected to receive either a 12-week buprenorphone-naloxone program, or a 14-day taper.
Source:
The Journal of the American Medical Association (JAMA) (2 votes)
Tags:
